Year None2022202120202019201820172016 Date Latest Press Release August 31, 2020 Eiger Announces Peginterferon Lambda - Lonafarnib Combination End of Treatment Results from Phase 2 LIFT HDV Study in Late Breaker Session at The Digital International Liver Congress™ 2020 August 6, 2020 Eiger BioPharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update August 3, 2020 Eiger BioPharmaceuticals to Participate in Upcoming August 2020 Investor Conferences May 29, 2020 Eiger BioPharmaceuticals, Inc. to Hold Virtual Annual Meeting of Stockholders on June 15, 2020 May 26, 2020 Eiger to Present at Jefferies Virtual Healthcare Conference 2020 May 19, 2020 Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies May 7, 2020 Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update April 30, 2020 Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda April 27, 2020 Eiger BioPharmaceuticals Announces EMA Validation of Lonafarnib MAA for Treatment of Progeria and Progeroid Laminopathies April 1, 2020 Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic Pagination First page « first Previous page ‹ previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page next › Last page last »
